Abstract:1155 Objectives Prostate specific membrane antigen (PSMA) is a membrane bound glycoprotein that is overexpressed on the cell surface of prostate cancer cells. A few PSMA-targeting radiotracers have been successfully introduced in clinical studies for imaging prostate cancer by PET. 18F-DCFPyL is currently the most sensitive tracer for the identification of PSMA-positive prostate cancer. However, the procedure for producing 18F-DCFPyL involves multiple synthesis steps. In this study, two 18F-labeled PSMA-targeting tracers (HTK-01069 and HTK-01070) that could be radiolabeled via 18F-19F isotope exchange on the ammoniomethyl-trifluoroborate (AmBF3) motif were synthesized and evaluated for PSMA imaging. Methods HTK-01069 was synthesized by coupling succinimido 4-(N-trifluoroborylmethyl-N,N-dimethylammonio)methylbenzoate to Lys-C(O)-Glu urea. HTK-01070 was prepared by coupling tetrafluorophenyl 4-(azidemethyl)benzoate to t-butyl protected Lys-C(O)-Glu urea, followed by deprotection and click reaction with N-propargyl-N,N-dimethyl-ammoniomethyltrifluoroborate. 18F-19F isotope exchange reactions were conducted for radiolabeling and both tracers were purified by HPLC. The stability of the tracers was assessed in mouse plasma for 2 h and LogD7.4 values were determined by the shake-flask method. PET imaging and biodistribution studies were performed in mice bearing PSMA-expressing LNCap prostate cancer xenografts. For blocking studies, mice were co-injected with 0.5 mg of DCFPyL. Results 18F-HTK-01069 and 18F-HTK-01070 were obtained in 9% and 3% decay-corrected radiochemical yields with > 99% radiochemical purity. The specific activities for 18F-HTK-01069 and 18F-HTK-01070 were 2.0 and 1.3 Ci/μmol, respectively. Both tracers were stable after 2 h incubation in plasma and were highly hydrophilic with LogD7.4 values between -3.4 and -4.3. From the PET and biodistribution data, 18F-HTK-01069 and 18F-HTK-01070 demonstrated clear PSMA-dependent uptake in LNCap prostate cancer xenografts at 1 h post-injection (p.i.). The clearance of both 18F-HTK-01069 and 18F-HTK-01070 was predominantly renal with minor involvement of the hepatobiliary pathway. At 1 h p.i., 18F-HTK-01070 exhibited higher tumour uptake (8.28 ± 1.25 %ID/g) than 18F-HTK-01069 (5.82 ± 1.09 %ID/g). 18F-HTK-01070 was also superior to 18F-HTK-01069 in terms of tumour-to-muscle ratio (37.7 ± 9.53 vs. 18.9 ± 6.05) and tumour-to-blood ratio (16.0 ± 1.37 vs. 11.9 ± 4.60). With PSMA blockade, uptake in tumours decreased significantly to 0.33 ± 0.07 and 0.27 ± 0.06 %ID/g for 18F-HTK-01069 and 18F-HTK-01070, respectively. Conclusions Two novel imaging agents, 18F-HTK-01069 and 18F-HTK-01070, were synthesized and evaluated for targeting PSMA expression with PET. Administration of 18F-HTK-01069 or 18F-HTK-01070 allowed for clear visualization of LNCap tumours in mice, with 18F-HTK-01070 yielding higher uptake and contrast. The data suggests that 18F-AmBF3-PSMA derivatives are promising agents for detecting PSMA-expressing prostate cancers.

Synthesis and Initial in Vivo Evaluation of A Radiofluorinated Sigma Receptor Radioligand for Prostate Tumor Imaging

Design and Investigation of a [18F]-Labeled Benzamide Derivative as a High Affinity Dual Sigma Receptor Subtype Radioligand for Prostate Tumor Imaging.

Novel 18F-Labeled Benzimidazolone-Based Radioligands As Highly Selective Sigma-2 Receptor Probes for Tumor Imaging

Development of a Highly Specific 18F-Labeled Benzimidazolonebased Sigma-2 Receptor Radioligand for Brain Tumor Imaging

Synthesis and evaluation of a (18) F-labeled 4-phenylpiperidine-4-carbonitrile radioligand for σ1 receptor imaging.

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

Synthesis and Biological Evaluation of 18F Labeled Fluoro-Oligo-ethoxylated 4-Benzylpiperazine Derivatives for Sigma-1 Receptor Imaging

Development of a Highly Specific 18 F-Labeled Radioligand for Imaging of the Sigma-2 Receptor in Brain Tumors

A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer.

Positron Emission Tomography Imaging Evaluation of a Novel <SUP>18</SUP>F-Labeled Sigma-1 Receptor Radioligand in Cynomolgus Monkeys

(18)F-Ambf3-mj9: a Novel Radiofluorinated Bombesin Derivative for Prostate Cancer Imaging.

F-18-Labeled 1,4-Dioxa-8-Azaspiro[4.5]Decane Derivative: Synthesis And Biological Evaluation Of A Sigma(1) Receptor Radioligand With Low Lipophilicity As Potent Tumor Imaging Agent

Design, synthesis and evaluation of novel prostate-specific membrane antigen-targeted aryl [ 18 F]fluorosulfate PET tracers

Synthesis and evaluation of novel 18F-labeled spirocyclic piperidine derivatives as σ1 receptor ligands for positron emission tomography imaging

Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: in Vivo Imaging in Experimental Models of Prostate Cancer.

Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

Radiofluorinated Rhenium Cyclized Α-Msh Analogues for PET Imaging of Melanocortin Receptor 1

Design, Synthesis and Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Aryl [18f]fluorosulfate Pet Tracers

Synthesis and Evaluation of F-18-Ambf3-Psma Derivatives As Pet Imaging Agents for Prostate Cancer

Synthesis and Preclinical Evaluation of an Al18F Radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA Ligand

F-Labeled benzylpiperazine derivatives as highly selective ligands for imaging σ receptor with positron emission tomography.